Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Paolo Verderio"'
Autor:
Francesca Ligorio, Serena Di Cosimo, Paolo Verderio, Chiara Maura Ciniselli, Sara Pizzamiglio, Lorenzo Castagnoli, Tiziana Triulzi, Elda Tagliabue, Sarra El-Abed, Miguel Izquierdo, Evandro de Azambuja, Paolo Nuciforo, Jens Huober, Luca Moscetti, Wolfgang Janni, M Coccia-Portugal, Paola Corsetto, Antonino Belfiore, Daniele Lorenzini, Maria Grazia Daidone, Andrea VIngiani, Serenella M Pupa, Giancarlo Pruneri, Claudio Vernieri
Publikováno v:
Cancer Research. 82:P2-13
Background: Despite great efforts to identify tumor-related prognostic biomarkers in early-stage Human Epidermal growth factor Receptor 2 (HER2)-positive Breast Cancer (HER2+ BC), reliable determinants of long-term clinical outcomes are lacking. HER2
Autor:
Marilena Valeria Iorio, Sara Pizzamiglio, Giulia Cosentino, Chiara M Ciniselli, Loris De Cecco, Alessandra Cataldo, Ilaria Plantamura, Tiziana Triulzi, Sarra El-abed, Yingbo Wang, Mohammed Bajji, Paolo Nuciforo, Jens Huober, Susan Ellard, David Rimm, Andrea Gombos, Mariagrazia Daidone, Paolo Verderio, Elda Tagliabue, Serena Di Cosimo
Publikováno v:
Cancer Research. 82:P5-13
Importance. Neoadjuvant therapy with dual HER2 blockade improved pathological complete response (pCR) rate. Nevertheless, it would be desirable to identify patients exquisitely responsive to single agent trastuzumab to minimize or avoid overtreatment
Autor:
Milena Perrone, Claudia Chiodoni, Mara Lecchi, Laura Botti, Barbara Bassani, Annamaria Piva, Elena Jachetti, Matteo Milani, Daniele Lecis, Elda Tagliabue, Paolo Verderio, Sabina Sangaletti, Mario P. Colombo
Publikováno v:
Cancer research.
Cancer is a systemic disease able to reprogram the bone marrow (BM) niche towards a protumorigenic state. The impact of cancer on specific BM subpopulations can qualitatively differ according to the signals released by the tumor, which can vary on th
Autor:
Roberto Ferrara, Giuseppe Lo Russo, Chiara Maura Ciniselli, Annamaria Piva, Barbara Bassani, Elena Jachetti, Giuseppina Calareso, Valeria Duroni, Settimio Di Gregorio, Claudia Proto, Arsela Prelaj, Alessandro De Toma, Mario Occhipinti, Marta Brambilla, Sara Manglaviti, Laura Mazzeo, Arturo Rinaldi, Teresa Beninato, Monica Ganzinelli, Filippo De Braud, Marina Chiara Garassino, Paolo Verderio, Mario Paolo Colombo, Sabina Sangaletti
Publikováno v:
Cancer Research. 83:5506-5506
Background: Hyperprogressive disease (HPD) has been described in ≃14-25% of pretreated non-small cell lung cancer (NSCLC) patients upon single-agent (SA) PD-1/PD-L1 inhibitors (ICI) and has not been reported upon platinum-based chemotherapy (PCT) a
Autor:
Giulia Cosentino, Sara Pizzamiglio, Chiara M. Ciniselli, Loris De Cecco, Alessandra Cataldo, Ilaria Plantamura, Tiziana Triulzi, Sarra El-abed, Yingbo Wang, Mohammed Bajji, Paolo Nuciforo, Jens Huober, Susan L. Ellard, David L. Rimm, Andrea Gombos, Mariagrazia Daidone, Paolo Verderio, Elda Tagliabue, Serena Di Cosimo, Marilena V. Iorio
Publikováno v:
Cancer Research. 82:1229-1229
The implementation of trastuzumab has revolutionized the clinical management of HER2 positive breast cancers. Unfortunately, 50% of patients are resistant to the treatment. Researchers have already designed alternative anti-HER2 agents, such as pertu
Autor:
Debora Fumagalli, L Pusztai, E. de Azambuja, L de la Pena, S. Di Cosimo, J. Baselga, M.J. Piccart, M. Izquierdo, L. De Cecco, Nadia Harbeck, Sara Pizzamiglio, J Huober, Tiziana Triulzi, Paolo Verderio, Elda Tagliabue
Publikováno v:
Cancer Research. 78:P2-09
BACKGROUND: As a neoadjuvant regimen for HER2-positive early breast cancer (BC), the use of two HER2-directed agents is more effective in producing pathological complete (pCR) responses than trastuzumab alone. Nevertheless, highly effective dual anti
Autor:
Florentine Hilbers, Paolo Verderio, Michael Untch, AV Salomon, Giovanni Apolone, Maria Grazia Daidone, J Huober, J. Baselga, Valentina Appierto, M.J. Piccart, S. Di Cosimo, M. Izquierdo, Fraser Symmans, L Pusztai, E. de Azambuja, P. Nuciforo, Sara Pizzamiglio, F. de Braud, L de la Pena, Kathleen I. Pritchard
Publikováno v:
Cancer Research. 79:P4-01
This abstract was withdrawn by the authors. Citation Format: Di Cosimo S, Appierto V, Pizzamiglio S, Baselga J, Piccart M, Huober J, Izquierdo M, de la Pena L, Hilbers F, de Azambuja E, Untch M, Pusztai L, Pritchard KI, Nuciforo P, Salomon AV, Symman
Autor:
Sara Pizzamiglio, L de la Pena, J. Baselga, F. de Braud, Valentina Appierto, Debora Fumagalli, S. Di Cosimo, Maria Grazia Daidone, J Huober, E. de Azambuja, Paola Tiberio, S. Bottelli, M.J. Piccart, Paolo Verderio, Marilena V. Iorio, Jan C. Brase
Publikováno v:
Cancer Research. 77:S3-02
Background A significant portion of breast cancer patients treated in the neoadjuvant setting does not achieve a pathological complete response (pCR) and has an increased risk of relapse after surgery. The current lack of reliable predictors of respo
Autor:
Filippo Spreafico, Maura Massimino, Italia Bongarzone, Ruben Magni, Lance A. Liotta, Alessandra Luchini, Paolo Verderio
Publikováno v:
Cancer Research. 74:1874-1874
Central nervous system (CNS) tumors are the second common pediatric malignancies, accounting for approximately 25% of all childhood neoplasms. Cerebrospinal fluid (CSF) is a very valuable source of biomarkers for brain tumors and represents a potenti
Autor:
Ermanno Leo, Marco A. Pierotti, Andrea Lampis, Federica Perrone, Sara Pizzamiglio, Claudia Bertan, Paolo Verderio, James F. Reid, Susanna Zanutto, Manuela Gariboldi, Viktorija Sokolova
Publikováno v:
Cancer Research. 70:4038-4038
MicroRNAs (miRNAs) are negative regulators of gene expression during various basic biological processes such as development, cellular differentiation, proliferation and apoptosis. Altered expression of miRNAs is associated with development and progre